CAS: 23256-50-0; 2-(2,6-Dichlorobenzylidene)Hydrazine-1-Carboximidamide Acetate
该化合物是一种具有抗血压特性的有选择性的α2-Adrenergy受体激动剂,其作用是集中减少同情性流出,导致外围血管抗药性和血压下降,其特点是受体特性高,行动时间长,有助于药理研究和实验研究; Guanabenz 乙酸乙酸乙酯也因其诱发蛋白反应途径的能力而具有潜在的...
- 英文名称2-(2,6-Dichlorobenzylidene)Hydrazine-1-Carboximidamide Acetate
- 中文名称4-咪唑乙酸盐酸盐
- IUPAC名称(E)-2-(2,6-dichlorobenzylidene)hydrazine-1-carboximidamide acetate
- 其它别名((2,6-dichlorobenzylidene)amino)-guanidinmonoacetate; 2-((2,6-dichlorophenyl)methylene)-hydrazinecarboximidamidmonoacetate; [2,6-DICHLOROBENZYLIDENE)-AMINO]GUANIDINE; [(2,6-DICHLOROBENZYLIDENE)AMINO]GUANIDINE ACETATE; GUANABENZ ACETATE; 3-[(2,6-dichlorophenyl)methylene]carbazamidine monoacetate
- CAS编号23256-50-0
- MFCD编号:MFCD00153801
- EINECS号:245-534-7
- FDA UNII编号:443O19GK1A
- 分子式:C10H12Cl2N4O2
- 分子量:291.14
- 产品CID: 1174222
- 同类组份化合物CAS23256-50-0 (acetate)5051-62-7 (free base)23113-43-1 (HCl)
- 产品分类原料药 → 循环系统用药 → 抗高血压病药
物理性质
MSDS等安全信息
欧盟法规
C&L通报REACH预注册合成工艺路线路线简述
海关参考信息
- 2902300000-甲苯
2903919090-氯苯
2912110000-甲醛
2912120000-乙醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.
专利号:AU-2007308022-A2
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
专利号:AU-2007308022-A1
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
专利号:US-2008107598-A1
优先权日:2006-10-05
标 题:Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications
专利号:AU-2007308022-B2
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
专利号:TR-2021011437-A2
优先权日:2020-12-29
标题 :SYNTHESIS OF PYRIMIDIN-4(1H)-ON DERIVATIVES FROM NEW HYDRAZINELIAN
网址: http://www.serpharm.cn
电话: 13951936332 18305166317👤
销售电话:13951936332 18305166317
邮箱：info@serpharm.com
电话: 13951936332 18305166317👤
📞南京江恒医药化工有限公司 ⚠️参考联系方式
销售电话:13951936332 18305166317
邮箱：info@serpharm.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领，请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实，百琢研不参与任何交易。企业认领注册入口→
⚠️ 未注册 · 未认证企业
备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议， 请通过页面底部联系方式告知我们，我们会尽快处理。第 1 / 1 页
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Igaki N, Yamada H, Oimomi M, Kasuga M. The effective inhibition of the Maillard reaction by guanabenz acetate, and its relevance to the prevention of diabetic complications. Clin Chim Acta. 1991 May 31;199(1):113-5. Portuguese.
合成参考文献
摘要:Yakuri to Chiryo. Pharmacology and Therapeutics., 10(4571), 1982
摘要:U.S. Pharmacopeia. The United States Pharmacopeia, USP 26/The National Formulary, NF 21; Rockville, MD: U.S. Pharmacopeial Convention, Inc., p885 (2003)
摘要:McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 93. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1993 (Plus Supplements, 1993)., p. 1055
摘要:Ellenhorn, M.J. and D.G. Barceloux. Medical Toxicology - Diagnosis and Treatment of Human Poisoning. New York, NY: Elsevier Science Publishing Co., Inc. 1988., p. 291
参考文献:10.1038/srep42017
摘要:Pathak BK, Mondal S, Banerjee S, Ghosh AN, Barat C. Sequestration of Ribosome during Protein Aggregate Formation: Contribution of ribosomal RNA. Scientific Reports. 2017 Feb 07;7(1):42017. doi: 10.1038/srep42017.
📝 需求与反馈
尽可能描述清楚需求与问题信息
